2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer

S L C Tagg; P A Foster; M P Leese; B V L Potter; M J Reed; A Purohit; S P Newman

doi:10.1038/sj.bjc.6604752

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer

S L C Tagg, P A Foster, M P Leese, B V L Potter, M J Reed, A Purohit, S P Newman

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

Drug combination therapy is a key strategy to improve treatment efficacy and survival of cancer patients. In this study the effects of combining 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140), a microtubule disruptor, with 2-deoxy-D-glucose (2DG) were assessed in MCF-7 (breast) and LNCaP (prostate) xenograft models in vivo. In mice bearing MCF-7 xenografts, daily p.o. administration of STX140 (5 mg kg(-1)) resulted in a 46% (P

Original language	English
Pages (from-to)	1842-8
Number of pages	7
Journal	British Journal of Cancer
Volume	99
Issue number	11
DOIs	https://doi.org/10.1038/sj.bjc.6604752
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6604752

Cite this

@article{4a7ad08bca984f8490e471b64b59801f,

title = "2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer",

abstract = "Drug combination therapy is a key strategy to improve treatment efficacy and survival of cancer patients. In this study the effects of combining 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140), a microtubule disruptor, with 2-deoxy-D-glucose (2DG) were assessed in MCF-7 (breast) and LNCaP (prostate) xenograft models in vivo. In mice bearing MCF-7 xenografts, daily p.o. administration of STX140 (5 mg kg(-1)) resulted in a 46% (P",

author = "Tagg, {S L C} and Foster, {P A} and Leese, {M P} and Potter, {B V L} and Reed, {M J} and A Purohit and Newman, {S P}",

year = "2008",

doi = "10.1038/sj.bjc.6604752",

language = "English",

volume = "99",

pages = "1842--8",

journal = "British Journal of Cancer",

publisher = "Cancer Research UK",

number = "11",

}

TY - JOUR

T1 - 2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination

T2 - a potential treatment for breast and prostate cancer

AU - Tagg, S L C

AU - Foster, P A

AU - Leese, M P

AU - Potter, B V L

AU - Reed, M J

AU - Purohit, A

AU - Newman, S P

PY - 2008

Y1 - 2008

N2 - Drug combination therapy is a key strategy to improve treatment efficacy and survival of cancer patients. In this study the effects of combining 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140), a microtubule disruptor, with 2-deoxy-D-glucose (2DG) were assessed in MCF-7 (breast) and LNCaP (prostate) xenograft models in vivo. In mice bearing MCF-7 xenografts, daily p.o. administration of STX140 (5 mg kg(-1)) resulted in a 46% (P

AB - Drug combination therapy is a key strategy to improve treatment efficacy and survival of cancer patients. In this study the effects of combining 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140), a microtubule disruptor, with 2-deoxy-D-glucose (2DG) were assessed in MCF-7 (breast) and LNCaP (prostate) xenograft models in vivo. In mice bearing MCF-7 xenografts, daily p.o. administration of STX140 (5 mg kg(-1)) resulted in a 46% (P

U2 - 10.1038/sj.bjc.6604752

DO - 10.1038/sj.bjc.6604752

M3 - Article

C2 - 18985042

VL - 99

SP - 1842

EP - 1848

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this